See below for a select group of presentations by LB Pharmaceuticals

October 2022October 2022 Corporate Presentation

December 2021American College of Neuropsychopharmacology Poster - "PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor engagement"
October 2021European College of Neuropsychopharmacology Poster – "LB-102 displays superior dopamine receptor occupancy compared to amisulpride in mouse and human PET studies"
April 2021B. Riley Securities’ Neuroscience Conference Webcast
September 2020European College of Neuropsychopharmacology Poster – “Safety, pharmacokinetics, and pharmacodynamics of LB-102, a selective D2/5-HT7 antagonist, in healthy volunteers" [PDF for download] [PDF of AE Chart]

May 2020    Journal of Nuclear Medicine Publication - Real-time LB-102 target engagement using [11C] Raclopride PET
September 2019European College of Neuropsychopharmacology Poster – “Building a translational bridge from animals to man for clinical candidate LB-102, a next-generation benzamide antipsychotic”
August 2019ACS Omega Publication- Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5‑HT7
January 2019Series A Corporate Presentation
October 2018 European College of Neuropsychopharmacology Poster - "LB-102, Potential Schizophrenia Treatment, Displays Polypharmacology as a Racemate—S Enantiomer Binds D2 Receptors and R Binds 5-HT7Receptor"
June 2018   One Page Corporate Summary
May 2018 Society of Biological Psychiatry Poster - "Establishing a PK-PD-E Relationship for Clinical Candidate LB-102, a Next-Generation Benzamide Antipsychotic"
March 2018 Sachs BioCapital USA Forum - Video of  Corporate Presentation
March 2018  Sachs BioCapital USA Forum - Corporate Presentation
October 2017 Additional IP/Patentability Due Diligence
September 2017European College of Neuropsychopharmacology Poster - "Pre-clinical Evaluation of Two Novel Benzamides LB-102 and 103 for the Treatment of Schizophrenia"





Want to learn more about LB Pharma?